Robert Bazemore has served as president and chief executive officer and member of the Board of Directors of Epizyme since September 2015.
Prior to joining Epizyme, Robert served as chief operating officer of Synageva BioPharma. While at Synageva, he helped to establish the company’s global commercial and medical organization to support the first product launch and helped lead the broader transition to a sustainable commercial enterprise through its acquisition in July 2015. Prior to that, Robert held several senior leadership positions at Johnson & Johnson, including president of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies ZYTIGA® and IMBRUVICA®. Robert also currently serves as a member of the Board of Directors of Ardelyx, Inc. He received a B.S. in biochemistry from the University of Georgia.